NL8004752A - Geneesmiddel tegen kanker op basis van een platina- verbinding, werkwijze voor de bereiding hiervan en de hierbij te gebruiken platinaverbinding. - Google Patents
Geneesmiddel tegen kanker op basis van een platina- verbinding, werkwijze voor de bereiding hiervan en de hierbij te gebruiken platinaverbinding. Download PDFInfo
- Publication number
- NL8004752A NL8004752A NL8004752A NL8004752A NL8004752A NL 8004752 A NL8004752 A NL 8004752A NL 8004752 A NL8004752 A NL 8004752A NL 8004752 A NL8004752 A NL 8004752A NL 8004752 A NL8004752 A NL 8004752A
- Authority
- NL
- Netherlands
- Prior art keywords
- platinum
- groups
- salts
- cis
- medicament according
- Prior art date
Links
- 150000003058 platinum compounds Chemical class 0.000 title claims description 15
- 238000002360 preparation method Methods 0.000 title claims description 8
- 238000000034 method Methods 0.000 title claims description 4
- 206010028980 Neoplasm Diseases 0.000 title description 18
- 201000011510 cancer Diseases 0.000 title description 11
- 150000001875 compounds Chemical class 0.000 claims description 24
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Substances [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims description 17
- -1 nitro, amino Chemical group 0.000 claims description 16
- 150000003839 salts Chemical class 0.000 claims description 15
- 229910052739 hydrogen Inorganic materials 0.000 claims description 11
- 239000001257 hydrogen Substances 0.000 claims description 11
- 239000003814 drug Substances 0.000 claims description 10
- 125000000217 alkyl group Chemical group 0.000 claims description 8
- 150000002431 hydrogen Chemical class 0.000 claims description 8
- 150000001412 amines Chemical class 0.000 claims description 7
- 229940045985 antineoplastic platinum compound Drugs 0.000 claims description 7
- 229910052736 halogen Inorganic materials 0.000 claims description 7
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 claims description 6
- 125000004442 acylamino group Chemical group 0.000 claims description 6
- 125000003545 alkoxy group Chemical group 0.000 claims description 6
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims description 6
- 125000000392 cycloalkenyl group Chemical group 0.000 claims description 6
- 150000002148 esters Chemical class 0.000 claims description 6
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims description 6
- 150000002367 halogens Chemical class 0.000 claims description 6
- 229910052697 platinum Inorganic materials 0.000 claims description 6
- 125000003118 aryl group Chemical group 0.000 claims description 5
- 125000004104 aryloxy group Chemical group 0.000 claims description 5
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 5
- NDBYXKQCPYUOMI-UHFFFAOYSA-N platinum(4+) Chemical class [Pt+4] NDBYXKQCPYUOMI-UHFFFAOYSA-N 0.000 claims description 5
- 125000003342 alkenyl group Chemical group 0.000 claims description 4
- 239000002246 antineoplastic agent Substances 0.000 claims description 3
- 229940041181 antineoplastic drug Drugs 0.000 claims description 3
- 125000001475 halogen functional group Chemical group 0.000 claims description 3
- 229910052760 oxygen Inorganic materials 0.000 claims description 3
- 239000001301 oxygen Substances 0.000 claims description 3
- 230000003381 solubilizing effect Effects 0.000 claims description 3
- 229910052717 sulfur Inorganic materials 0.000 claims description 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 2
- 239000013543 active substance Substances 0.000 claims description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 2
- 239000011593 sulfur Substances 0.000 claims description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- JVBXVOWTABLYPX-UHFFFAOYSA-L sodium dithionite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])=O JVBXVOWTABLYPX-UHFFFAOYSA-L 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- 229910019032 PtCl2 Inorganic materials 0.000 description 4
- 125000003277 amino group Chemical group 0.000 description 4
- 208000032839 leukemia Diseases 0.000 description 4
- 125000002577 pseudohalo group Chemical group 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 3
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical group N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 231100001274 therapeutic index Toxicity 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 2
- 239000003570 air Substances 0.000 description 2
- 150000001450 anions Chemical group 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- UNSNICPSZOKZNS-UHFFFAOYSA-L cyclopentanamine dichloroplatinum Chemical compound Cl[Pt]Cl.NC1CCCC1 UNSNICPSZOKZNS-UHFFFAOYSA-L 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 238000002329 infrared spectrum Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 241000220438 Arachis Species 0.000 description 1
- 235000003911 Arachis Nutrition 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 1
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- KZOWNALBTMILAP-JBMRGDGGSA-N ancitabine hydrochloride Chemical compound Cl.N=C1C=CN2[C@@H]3O[C@H](CO)[C@@H](O)[C@@H]3OC2=N1 KZOWNALBTMILAP-JBMRGDGGSA-N 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 150000001540 azides Chemical class 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- XLJMAIOERFSOGZ-UHFFFAOYSA-M cyanate Chemical compound [O-]C#N XLJMAIOERFSOGZ-UHFFFAOYSA-M 0.000 description 1
- 125000006165 cyclic alkyl group Chemical group 0.000 description 1
- NISGSNTVMOOSJQ-UHFFFAOYSA-N cyclopentanamine Chemical compound NC1CCCC1 NISGSNTVMOOSJQ-UHFFFAOYSA-N 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000000921 elemental analysis Methods 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229910003002 lithium salt Inorganic materials 0.000 description 1
- 159000000002 lithium salts Chemical class 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- HRGDZIGMBDGFTC-UHFFFAOYSA-N platinum(2+) Chemical compound [Pt+2] HRGDZIGMBDGFTC-UHFFFAOYSA-N 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 125000003107 substituted aryl group Chemical group 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
- C07F15/0006—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table compounds of the platinum group
- C07F15/0086—Platinum compounds
- C07F15/0093—Platinum compounds without a metal-carbon linkage
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB7929442 | 1979-08-23 | ||
| GB7929442 | 1979-08-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NL8004752A true NL8004752A (nl) | 1981-02-25 |
Family
ID=10507399
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NL8004752A NL8004752A (nl) | 1979-08-23 | 1980-08-22 | Geneesmiddel tegen kanker op basis van een platina- verbinding, werkwijze voor de bereiding hiervan en de hierbij te gebruiken platinaverbinding. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US4329299A (xx) |
| JP (1) | JPS5653693A (xx) |
| BE (1) | BE884886A (xx) |
| CA (1) | CA1164882A (xx) |
| CH (1) | CH644516A5 (xx) |
| DE (1) | DE3031732A1 (xx) |
| FR (1) | FR2463776A1 (xx) |
| GB (1) | GB2060615B (xx) |
| IT (1) | IT1194947B (xx) |
| NL (1) | NL8004752A (xx) |
| ZA (1) | ZA805101B (xx) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4533502A (en) * | 1983-02-22 | 1985-08-06 | Rochon Fernande D | Platinum (II) compounds and their preparation |
| GB8328218D0 (en) * | 1983-10-21 | 1983-11-23 | Johnson Matthey Plc | Oral compositions |
| GB2163163B (en) * | 1984-01-23 | 1987-10-07 | Inst Obschei I Neoorganichesko | Blended carboxylate complexes of platinum |
| US4599352A (en) * | 1984-03-01 | 1986-07-08 | The United States Of America As Represented By The Department Of Health And Human Services | Antineoplastic platinum (IV) complexes and compositions |
| FR2563524B1 (fr) * | 1984-04-25 | 1987-03-20 | Inst Obschei I Neoorganichesko | Complexes mixtes carboxylatoplatine (ii) et procede de preparation desdits complexes |
| GB8416048D0 (en) * | 1984-06-22 | 1984-07-25 | Johnson Matthey Plc | Anti-tumour compounds of platinum |
| US4658047A (en) * | 1985-09-27 | 1987-04-14 | The United States Of America As Represented By The Department Of Health And Human Services | Method of preparing 1,2-diaminocyclohexane tetrachloro platinum (IV) isomers |
| GB8806044D0 (en) * | 1988-03-14 | 1988-04-13 | Johnson Matthey Plc | Platinum coordination compounds |
| GB9105037D0 (en) * | 1991-03-09 | 1991-04-24 | Johnson Matthey Plc | Improvements in chemical compounds |
| JP3492763B2 (ja) | 1994-06-03 | 2004-02-03 | エスエス製薬株式会社 | 白金錯体及びこれを含有する悪性腫瘍治療剤 |
| CN1080157C (zh) * | 1995-10-06 | 2002-03-06 | 罗伯特-博希股份公司 | 带工具夹头和相应工具的手工工具机 |
| CZ288406B6 (en) * | 1998-05-27 | 2001-06-13 | Lachema Np | Platinum complex of oxidation number II, process for preparing such complex, the complex functioning as medicament and pharmaceutical composition in which the complex is comprised |
| ES2253214T3 (es) * | 1999-04-13 | 2006-06-01 | Anormed Inc. | Proceso para preparar complejos amina-platino. |
| JP4776843B2 (ja) | 1999-10-01 | 2011-09-21 | イムノゲン インコーポレーティッド | 免疫複合体及び化学療法剤を用いる癌治療用組成物及び方法 |
| GB0011903D0 (en) * | 2000-05-18 | 2000-07-05 | Astrazeneca Ab | Combination chemotherapy |
| US6894049B1 (en) | 2000-10-04 | 2005-05-17 | Anormed, Inc. | Platinum complexes as antitumor agents |
| ES2308451T3 (es) | 2004-02-18 | 2008-12-01 | Gpc Biotech Ag | Satraplatino para el tratamiento de tumores resistentes o refractarios. |
| EP1781230A1 (en) * | 2004-07-14 | 2007-05-09 | GPC Biotech AG | Variable-dose packaging system |
| US8178564B2 (en) * | 2006-11-06 | 2012-05-15 | Poniard Pharmaceuticals, Inc. | Use of picoplatin to treat colorectal cancer |
| US8173686B2 (en) | 2006-11-06 | 2012-05-08 | Poniard Pharmaceuticals, Inc. | Use of picoplatin to treat colorectal cancer |
| US8168662B1 (en) | 2006-11-06 | 2012-05-01 | Poniard Pharmaceuticals, Inc. | Use of picoplatin to treat colorectal cancer |
| US8168661B2 (en) * | 2006-11-06 | 2012-05-01 | Poniard Pharmaceuticals, Inc. | Use of picoplatin to treat colorectal cancer |
| US20110033528A1 (en) * | 2009-08-05 | 2011-02-10 | Poniard Pharmaceuticals, Inc. | Stabilized picoplatin oral dosage form |
| US20100260832A1 (en) * | 2007-06-27 | 2010-10-14 | Poniard Pharmaceuticals, Inc. | Combination therapy for ovarian cancer |
| TW200916094A (en) * | 2007-06-27 | 2009-04-16 | Poniard Pharmaceuticals Inc | Stabilized picoplatin dosage form |
| US20100310661A1 (en) * | 2007-07-16 | 2010-12-09 | Poniard Pharmaceuticals, Inc. | Oral formulations for picoplatin |
| AU2009210734A1 (en) * | 2008-02-08 | 2009-08-13 | Poniard Pharmaceuticals, Inc. | Picoplatin and amrubicin to treat lung cancer |
| RU2569646C2 (ru) * | 2013-11-28 | 2015-11-27 | Федеральное государственное бюджетное учреждение науки Институт неорганической химии им. А.В. Николаева Сибирского отделения Российской академии наук | Способ получения тетрахлороплатоат (ii)-иона и его солей с натрием, калием или аммонием |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH588505A5 (xx) * | 1972-06-08 | 1977-06-15 | Research Corp | |
| GB1578323A (en) * | 1976-02-26 | 1980-11-05 | Rustenburg Platinum Mines Ltd | Compositions containing platinum |
| SE447902B (sv) * | 1977-10-19 | 1986-12-22 | Johnson Matthey Co Ltd | Cis-koordinationsforening av platina och komposition innehallande foreningen |
-
1980
- 1980-08-20 US US06/179,786 patent/US4329299A/en not_active Expired - Lifetime
- 1980-08-20 GB GB8027080A patent/GB2060615B/en not_active Expired
- 1980-08-20 ZA ZA00805101A patent/ZA805101B/xx unknown
- 1980-08-21 FR FR8018265A patent/FR2463776A1/fr active Granted
- 1980-08-21 CA CA000358754A patent/CA1164882A/en not_active Expired
- 1980-08-22 NL NL8004752A patent/NL8004752A/nl not_active Application Discontinuation
- 1980-08-22 CH CH634880A patent/CH644516A5/fr not_active IP Right Cessation
- 1980-08-22 DE DE19803031732 patent/DE3031732A1/de active Granted
- 1980-08-22 JP JP11575380A patent/JPS5653693A/ja active Pending
- 1980-08-22 BE BE0/201835A patent/BE884886A/fr not_active IP Right Cessation
- 1980-08-25 IT IT12631/80A patent/IT1194947B/it active
Also Published As
| Publication number | Publication date |
|---|---|
| GB2060615B (en) | 1983-06-22 |
| DE3031732A1 (de) | 1981-03-12 |
| FR2463776B1 (xx) | 1985-03-22 |
| FR2463776A1 (fr) | 1981-02-27 |
| ZA805101B (en) | 1981-08-26 |
| CA1164882A (en) | 1984-04-03 |
| IT8012631A0 (it) | 1980-08-25 |
| GB2060615A (en) | 1981-05-07 |
| US4329299A (en) | 1982-05-11 |
| CH644516A5 (fr) | 1984-08-15 |
| JPS5653693A (en) | 1981-05-13 |
| BE884886A (fr) | 1980-12-16 |
| DE3031732C2 (xx) | 1992-10-29 |
| IT1194947B (it) | 1988-09-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NL8004752A (nl) | Geneesmiddel tegen kanker op basis van een platina- verbinding, werkwijze voor de bereiding hiervan en de hierbij te gebruiken platinaverbinding. | |
| AU2002329097B2 (en) | Inclusion compound comprising cucurbituril derivatives as host molecule and pharmaceutical composition comprising the same | |
| AU2004264421B2 (en) | Platinum complexes for the treatment of tumors | |
| EP0679656B1 (en) | Improvements in platinum complexes | |
| Hoeschele et al. | Synthesis, structural characterization, and antitumor properties of a novel class of large-ring platinum (II) chelate complexes incorporating the cis-1, 4-diaminocyclohexane ligand in a unique locked boat conformation | |
| JPS6326116B2 (xx) | ||
| CS239911B2 (en) | Processing of complexed diamino platinum | |
| GB2091731A (en) | Platinum complexes | |
| US4657927A (en) | Malonato platinum compounds | |
| US4900756A (en) | (2,2-bis(aminomethyl)-1,3-propranediol-N,N')platinum complexes | |
| JPH036156B2 (xx) | ||
| Raudaschl-Sieber et al. | Reaction of cyanide with platinum-nucleobase complexes: preparative, spectroscopic, and structural studies. Unexpected stability of platinum-thymine and platinum-uracil complexes | |
| US4584316A (en) | Palladium anti-cancer complexes | |
| US4687780A (en) | Anti-tumor compounds of platinum | |
| HRP20000792A2 (en) | Platinum complex, its preparation and therapeutic application | |
| US6011166A (en) | Trinuclear cationic platinum complexes having antitumor activity and pharmaceutial compositions containing them | |
| EP0897389B1 (fr) | Complexes de platine dinucleaires, procede pour leur preparation et compositions pharmaceutiques en contenant | |
| WO2004099224A1 (de) | Carboplatin-artige platin (ii)- komplexe | |
| FI83086C (fi) | Foerfarande foer framstaellning av komplex med tumormotverkande effekt. | |
| US4416878A (en) | [8-(Dialkylamino alkoxy)-caffeine]-platinum complex compounds and pharmaceutical products containing the same | |
| EP0304566A2 (en) | Water soluble platinum complexes of novel malonate derivatives | |
| EP0232784B1 (en) | (gem-heterocyclodimethanamine-n,n')platinum complexes | |
| RU2699809C9 (ru) | Катионно - анионные комплексы палладия | |
| EP0210291A1 (en) | Platinum complexes of antitumor agents | |
| RU2033998C1 (ru) | Комплексное соединение цис-диаминоплатины (ii) с сополимером na-соли малеиновой кислоты и фурана, обладающее иммуностимулирующей и противоопухолевой активностью, с широким интервалом терапевтических доз при низкой нефротоксичности |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A85 | Still pending on 85-01-01 | ||
| BA | A request for search or an international-type search has been filed | ||
| BB | A search report has been drawn up | ||
| BC | A request for examination has been filed | ||
| BI | The patent application has been withdrawn |